Global Scalp Cool Devices for Chemotherapy Induced Hair Loss Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Scalp Cool Devices for Chemotherapy Induced Hair Loss Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Hair loss is a potentially distressing side effect of several cytotoxic drugs. Scalp cooling has been suggested to prevent hair loss. A Medicare National Coverage Determination explains that keeping the scalp cool during chemotherapy has been noted to reduce the risk of hair loss.

Market Overview:

The latest research study on the global Scalp Cool Devices for Chemotherapy Induced Hair Loss market finds that the global Scalp Cool Devices for Chemotherapy Induced Hair Loss market reached a value of USD 28.95 million in 2022. It’s expected that the market will achieve USD 55.2 million by 2028, exhibiting a CAGR of 11.36% during the forecast period.

Influence of COVID-19 Outbreak on Scalp Cool Devices for Chemotherapy Induced Hair Loss Industry Development

The impact of COVID-19 on the Scalp Cool Devices for Chemotherapy Induced Hair Loss industry will involve all major links and all entities in the industry chain. The company's management efficiency has declined, commuting has been severely hindered, production plans have been severely hindered, network expansion has been delayed, marketing has been delayed, brand adjustments have been forced, market sales have declined, and company and employee revenue have declined. The impact on Scalp Cool Devices for Chemotherapy Induced Hair Loss depends on the prevention and control of COVID-19.

COVID-19 has affected the tension of raw materials, logistics will be suspended, and the supply of raw materials for Scalp Cool Devices for Chemotherapy Induced Hair Loss will be tight. Production has stalled, the company's inventory has increased, and the production of its affiliates in the worst-hit areas has been greatly affected. The short-term epidemic has little effect on the supply of raw materials for enterprises, and the long-term epidemic will cause inestimable losses. If the outbreak further develops and the logistics are always unsatisfactory, then the small and medium-sized Scalp Cool Devices for Chemotherapy Induced Hair Loss company is likely to be closed.

Market Challenges

The Scalp Cool Devices for Chemotherapy Induced Hair Loss market is highly concentrated, with the top three players occupying more than 63% of the market. And these participants with a large market share generally have a broad and stable customer base. Therefore, for new entrants, this not only poses financial challenges, but also has certain barriers in terms of downstream customer resources. In addition, Scalp Cool Devices for Chemotherapy Induced Hair Loss is a medical device. Different countries have different laws and regulations for medical devices. They cannot enter the market without the approval of relevant departments. For example, in the United States, the FDA initially cleared the device, the DigniCap® Scalp Cooling System, for patients with breast cancer in 2015. On April 19, 2017, the Paxman Scalp Cooling System received US Food and Drug Administration (FDA) clearance. This is the second scalp cooling system approved by the FDA. So different Regional regulations for medical equipment are also one of the important challenges for Scalp Cool Devices for Chemotherapy Induced Hair Loss in its multi-regional development.

Region Overview:

From 2023-2028, Europe is estimated to witness robust growth prospects.

Company Overview:

Paxman is one of the major players operating in the Scalp Cool Devices for Chemotherapy Induced Hair Loss market, holding a share of 40.61% in 2020.

Paxman has been pioneering scalp cooling technology worldwide for over 25 years. Having carried out extensive trials and product development, they have created a system that is clinically proven, cost-effective and widely embraced by doctors, nurses and patients alike. They are committed to improving the efficacy of scalp cooling for all patients across the world.

Dignitana AB designs, develops, and markets hair loss prevention systems. The Company's products cool the head in order to reduce the amount of hair loss in cancer patients during treatment.

Segmentation Overview:

Among different product types, Scalp Cool Systems segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Breast Cancer segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Scalp Cool Devices for Chemotherapy Induced Hair Loss market covered in Chapter 3:

Arctic Cold Caps
Penguin Cold Caps
Dignitana
Chemo Cold Caps
Paxman

In Chapter 4 and Chapter 14.2, on the basis of types, the Scalp Cool Devices for Chemotherapy Induced Hair Loss market from 2018 to 2029 is primarily split into:

Scalp Cool Caps
Scalp Cool Systems

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Scalp Cool Devices for Chemotherapy Induced Hair Loss market from 2018 to 2029 covers:

Breast Cancer
Prostate Cancer
Ovarian Cancer
Lung Cancer
Other Solid Tumors

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)